Document is current
Any future updates will be listed below
-
Authors
Klemenzdottir, Elin Ola
Arnadottir, Gudny Anna https://orcid.org/0000-0001-6571-423X
Jensson, Brynjar Orn https://orcid.org/0000-0002-2252-4134
Jonasdottir, Adalbjorg
Katrinardottir, Hildigunnur
Fridriksdottir, Run
Jonasdottir, Aslaug
Sigurdsson, Asgeir
Gudjonsson, Sigurjon Axel
Jonsson, Jon Johannes
Stefansdottir, Vigdis https://orcid.org/0000-0003-4451-3126
Danielsen, Ragnar
Palsdottir, Astridur
Jonsson, Hakon
Helgason, Agnar https://orcid.org/0000-0002-8545-3767
Magnusson, Olafur Thor
Thorsteinsdottir, Unnur
Bjornsson, Hans Tomas
Stefansson, Kari https://orcid.org/0000-0003-1676-864X
Sulem, Patrick https://orcid.org/0000-0001-7123-6123
- License Information
-
More Information
Article History
Received: 20 September 2022
Revised: 18 August 2023
Accepted: 30 August 2023
First Online: 8 September 2023
Competing interests
: Authors affiliated with deCODE Genetics/Amgen declare competing interests as employees. HTB is a Consultant for Mahzi therapeutics. The remaining authors declare no competing financial interest.
: The case series study (patient identifiers) was approved by the Icelandic Ethics Committee (Vísindasiðanefnd). The database study (no patient identifiers) has prior approval by the Icelandic Ethics Committee (Vísindasiðanefnd) but all participating individuals, or their guardians, have given informed consent prior to participation. All sample identifiers are encrypted in accordance with the regulations of the Icelandic Data Protection Authority. No single person was simultaneously able to access data with or without identifiers. Approval for these studies was provided by the National Bioethics Committee and the Icelandic Data Protection Authority.
